A novel estrogen receptor 1: sphingomyelin phosphodiesterase acid-like 3B pathway mediates rituximab response in myositis patients Article (Faculty180)

cited authors

  • Parkes, Joanna E; Boehler, Jessica F; Li, Ning; Kendra, Ryan M; O'Hanlon, Terrance P; Hoffman, Eric P; Peterson, Jennifer M; Miller, Frederick W; Rider, Lisa G; Nagaraju, Kanneboyina


  • The B-cell depleting biologic, rituximab, is used to treat refractory autoimmune myositis. However, the beneficial effects of rituximab appear to outweigh the known contribution of B cells in myositis. We aimed to elucidate how myositis patients respond differently to rituximab and possible alternative mechanisms of action.

publication date

  • 2023

published in

start page

  • 2864

end page

  • 2871


  • 62